Late-StageResearch compoundATC · N06BA07Rx · Prescription only (Rx), DEA Schedule IV (USA), specialist recommended in HU

Modafinil

Wakefulness-promoting agent, FDA-approved for narcolepsy, shift work sleep disorder, OSA adjunct. DEA Schedule IV. Off-label cognitive enhancement framing separate in MolekulaX Nootropic library.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Modafinil vial

WHAT IS MODAFINIL?

Detailed overview

Modafinil is a wakefulness-promoting agent developed by Cephalon (now Teva) (Provigil, FDA 1998). ATC code N06BA07 (CNS stimulants). Official FDA indications: narcolepsy, shift work sleep disorder (SWSD), obstructive sleep apnea (OSA) residual sleepiness adjunct. Clinically documented off-label use (cognitive enhancement, fatigue reduction, MS-associated fatigue, second-line ADHD) is detailed in the MolekulaX Nootropic library. This pharma entry focuses on official Rx indications. Mechanism: dopamine reuptake inhibitor (DAT), activation of histamine and orexin systems in the hypothalamus, selectively promoting wakefulness without the global CNS activation of classic stimulants (amphetamine, methylphenidate).

ATC code

N06BA07

Prescription

Prescription only (Rx), DEA Schedule IV (USA)

Mechanism

DAT inhibitor + histamine/orexin activation

Half-life

12-15 h

Onset

30-60 min, peak 2-4 h

Data console

Lab data

/lab/molecular-data.jsonLIVE
> ATC codeN06BA07
> PrescriptionPrescription only (Rx), DEA Schedule IV (USA), specialist recommended in HU
> MechanismSelective low-affinity dopamine transporter (DAT) inhibitio…
> Half-life12-15 h (parent); R-modafinil 14-16 h, S-modafinil 4-5 h (armodafinil = R-enantiomer)
> Onset30-60 min, peak plasma 2-4 h
> BioavailabilityNot determined (aqueous insolubility precludes IV); oral tablet ≈ aqueous suspension – FDA Provigil label

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Serious skin and hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, multi-organ hypersensitivity), typically in the first 1–4 weeks, FDA serious warning, stop immediately at any rash.
  • Psychiatric effects: anxiety, irritability, insomnia, and less commonly mania, psychosis, hallucinations, aggression and suicidal ideation, especially with a psychiatric history.
  • Cardiovascular effects: mild increases in blood pressure and heart rate, palpitations, rarely chest pain and arrhythmia; blood pressure monitoring advised.
  • Headache (the most common, around 35%), usually easing after the first week.
  • Nausea, dry mouth, decreased appetite and weight loss.
  • Insomnia if dosed too late in the day (around ≥2 pm), so once-daily morning dosing is recommended.
  • Psychological dependence and abuse potential (DEA Schedule IV, low but not zero), especially when tied to performance expectations; physical tolerance is rare.

Contraindications · 4

  • Prior severe skin reaction (Stevens-Johnson syndrome, TEN, DRESS) history
  • Severe CV disease: LV hypertrophy, mitral valve prolapse with IHSS
  • Known modafinil hypersensitivity
  • Psychosis, severe anxiety disorder (relative)

Related Pharmaceuticals

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Modafinil?

Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: June 19, 2026

The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.